Figure 2
From: Discovery of a new class of integrin antibodies for fibrosis
MK-0429 inhibits lung fibrosis in the bleomycin mouse model. (A) Schematics of compound administration in BLM model. 5 days after BLM intra-tracheal instillation, the animals were given MK-0429 (200 mpk via osmotic minipump for 2 weeks) or Nintedanib (60 mpk po qd for 2 weeks). Lungs were collected at Day 19 for histological and biochemical evaluation. mpk, milligrams per kilogram body weight; po, Per os, oral administration; qd, Quaque die, every day. (B) Plasma total drug concentration was measured 2 h after final oral dose at Day 19. (C) Representative Masson Trichrome staining of mouse lungs. a and d, saline intra-tracheal instillation; b-f, BLM intra-tracheal instillation; a and d, no compound treatment; b, vehicle in minipump; c, MK-0429 in minipump; e, vehicle po; f, Nintedanib po. D) Modified Ashcroft scores of mouse lung. Mean ± SEM, n = 10. One-way ANOVA followed by Tukey’s test, *p < 0.05, **p < 0.01, ***p < 0.005 vs BLM-vehicle group. (E) Total inflammation area in mouse lungs. Mean ± SEM, n = 10. One-way ANOVA followed by Tukey’s test, *p < 0.05, **p < 0.01, ***p < 0.005 vs BLM-vehicle group. (F) Immunohistochemical analysis of αSMA. Mean ± SEM, n = 10. One-way ANOVA followed by Tukey’s test, *p < 0.05, **p < 0.01, ***p < 0.005 vs BLM-vehicle group. (G) Soluble collagen content in bronchoalveolar lavage fluid (BALF). Mean ± SEM, n = 10. *p < 0.05, **p < 0.01, ***p < 0.005 vs BLM-vehicle group.
